MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/02770903.2024.2449233

Медицинская библиотека · The Journal of asthma : official journal of the Association for the Care of Asthma · 2025

Regional challenges to optimize the management of patients with severe asthma type 2 inflammation: a Delphi consensus in seven countries.

Heaney Liam G, Larenas-Linnemann Desiree, Al-Lehebi Riyad, Athanazio Rodrigo, Barria Paulina, Munive Abraham Ali, Colodenco Daniel, Yañez Anahi, Jimenez Libardo, Pizzichini Marcia M, Talwar Deepak, Pizzichini Emilio, Levy Gur, Laucho-Contreras Maria E

СтатьяConsensus StatementПеревод в очереди

Аннотация

Objective

Severe asthma burdens patients and presents clinical management challenges for healthcare professionals. Biologics are crucial interventions for severe type two (T2) patients with high eosinophil counts. We conducted a Delphi consensus in seven developing or typically underrepresented countries to understand expert agreement on managing severe asthma with type two (T2) inflammation.

Methods

The study comprised two online survey rounds and a participant meeting, involving 21 and 20 respiratory experts in the first and second survey, respectively. We developed a 70-statement questionnaire after literature review. Responses were recorded on a Likert scale (0-9) with 75% consensus threshold.

Results

Consensus was reached on 37/60 closed-ended questions, including subtypes, in survey-1 and 20/47 closed-ended questions in survey-2. 95% of participants agreed on biomarker use for biologic treatment selection. 100% agreed timely biologic treatment leads to improvement in patients with severe asthma and an eosinophilic phenotype. 90% agreed to avoid maintenance oral corticosteroids (OCS) and start biologic therapy directly. Experts defined clinical remission on treatment as no exacerbations, no OCS use, Asthma Control Questionnaire (ACQ)-5 score < 1.5, and lung function optimization (forced expiratory volume in one second [FEV1] ≥ 80% of predicted or pre-bronchodilator FEV1 increase ≥ 100 mL from baseline). In survey-1, 81% agreed these outcomes are achievable in practice. All referral statements achieved consensus.

Conclusions

This Delphi study focused on understanding patients with severe asthma and T2 inflammation in developing/underrepresented countries. Appropriately utilizing biomarkers, timely treatment interventions for best outcomes, expert consensus on clinical remission, and referral are crucial for improving patient management.

Для цитирования: Heaney Liam G, Larenas-Linnemann Desiree, Al-Lehebi Riyad, Athanazio Rodrigo, Barria Paulina, Munive Abraham Ali, Colodenco Daniel, Yañez Anahi, Jimenez Libardo, Pizzichini Marcia M, Talwar Deepak, Pizzichini Emilio, Levy Gur, Laucho-Contreras Maria E. Regional challenges to optimize the management of patients with severe asthma type 2 inflammation: a Delphi consensus in seven countries.. The Journal of asthma : official journal of the Association for the Care of Asthma. 2025. DOI: 10.1080/02770903.2024.2449233.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.